Comparing the current results to its competitors, Prokidney reported Revenue decrease in the 2 quarter 2026 year on year by -32.13 %, despite the revenue increase by the most of its competitors of 11.69 %, recorded in the same quarter.
November 6, 2025
The landscape of chronic kidney disease (CKD) therapeutics is rapidly evolving, with emerging cell therapies offering new hope for patients suffering from advanced stages of the disease. At the forefront of this innovation is ProKidney Corp. (Nasdaq: PROK), a late clinical-stage cell therapy company dedicated to addressing the dire unmet needs of CKD patients, particularly those grappling with diabetes. Recently, ProKidney presented the full results of its Phase 2 REGEN-007 trial for its flagship product, rilparencel, at the American Society of Nephrology s Kidney Week 2025. These results reaffirm the potential of rilparencel as a transformative treatment for advanced CKD, setting the stage for ProKidney’s...
June 10, 2024
Renal Autologous Cell Therapy Shows Promise: Interim Results from ProKidney s REGEN-007 Phase 2 Trial Authors: Author Names, CSIMarket.com In a recent announcement, ProKidney Corp. (Nasdaq: PROK), a prominent late clinical-stage cellular therapeutics company specializing in chronic kidney disease (CKD), has reported encouraging interim results from its Phase 2 REGEN-007 trial. The trial evaluates its pioneering renal autologous cell therapy, rilparencel, in patients with CKD induced by diabetes. These findings, disclosed on June 10, 2024, could signify a promising advancement in the treatment landscape for diabetic CKD. Trial Overview and MethodologyThe REGEN-007 Phase 2 trial is a multicenter, randomized,...
Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.
Cardiol Therapeutics Inc. operates on a business model focused on the research and development of pharmaceutical-grade cannabidiol (CBD) and targeted therapies for cardiovascular diseases. The company aims to leverage its expertise to develop innovative and effective treatments to address unmet medical needs in the field of heart-related conditions.
Cullinan Oncology Inc's business model focuses on developing innovative cancer treatments by identifying and acquiring promising drug candidates through collaborations and partnerships with academic institutions and biotechnology companies. They prioritize the advancement of these therapies towards clinical trials and commercialization, aiming to address unmet medical needs in the field of oncology.
Biontech SE's business model focuses on the development and commercialization of novel mRNA-based immunotherapies for various diseases, including cancer.
Biogen Incs business model focuses on researching, developing, and commercializing innovative therapies primarily for neurological and neurodegenerative diseases, emphasizing advancements in precision medicine and patient care.
Sources:
Prokidney Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Prokidney Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
